Mounjaro and Zepbound contain the same active ingredient—tirzepatide—but they have different FDA-approved indications and product-specific dose instructions. Current Mounjaro labeling includes type 2 diabetes in adults and pediatric patients 10 years and older; current Zepbound labeling includes chronic weight management and moderate-to-severe obstructive sleep apnea in defined populations.
That distinction matters because people often hear about tirzepatide as if it were one product. Biologically, it is one molecule. Practically, the brand name on the box can affect why it was prescribed, what your plan covers, what outcomes your prescriber is monitoring, and how you organize your dose history.
The Short Version: Same Molecule, Different Label
Tirzepatide is a once-weekly injectable medication that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Eli Lilly markets tirzepatide as Mounjaro for type 2 diabetes and as Zepbound for weight-management indications.
The current Mounjaro prescribing information and Zepbound prescribing information define the exact indicated populations, limitations, and presentation-specific instructions.
So if someone asks, "Is Zepbound just Mounjaro?" the accurate answer is: same active ingredient, different FDA-approved use and product label.
| Question | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA-approved use | Type 2 diabetes glycemic control in the populations stated in the current label | Chronic weight management; moderate-to-severe OSA in the population stated in the current label |
| Schedule | Once weekly injection | Once weekly injection |
| Dose strengths | 2.5 mg through 15 mg | 2.5 mg through 15 mg |
| Starting dose | 2.5 mg once weekly | 2.5 mg once weekly |
| Adult maximum | 15 mg once weekly | 15 mg once weekly |
| Pediatric maximum | 10 mg once weekly for Mounjaro patients age 10+ (Mounjaro prescribing information) | See Zepbound's distinct indicated populations |
Dosing: Similar Strengths, Product-Specific Instructions
The adult initiation language in both labels starts at 2.5 mg once weekly and increases to 5 mg after four weeks. The current Mounjaro label sets a maximum of 15 mg once weekly in adults and 10 mg once weekly in pediatric patients age 10 years and older. Further increases and maintenance choices must be read from the exact product and population label; overlapping strengths do not make every dose a mandatory step or every indication's plan identical.
The labels identify 2.5 mg as an initiation dose rather than a maintenance choice in the relevant adult schedules. That does not predict how the first month will feel or what result an individual will have.
For a deeper step-by-step explanation, see our tirzepatide dosing schedule. If you are logging the medication itself, the relevant tracker pages are Mounjaro tracker, Zepbound tracker, and tirzepatide tracker.
Why the Brand Name Still Matters
Even when the molecule and available strengths overlap, the brand name is not just cosmetic.
Your treatment goal may differ. With Mounjaro, your prescriber may focus heavily on A1C, fasting glucose, hypoglycemia risk with other diabetes medications, and cardiometabolic markers. With Zepbound, the central goals may include weight change, waist circumference, sleep apnea symptoms, and long-term tolerability.
Insurance coverage may differ. Many insurance plans separate diabetes drugs from anti-obesity medications. A plan may cover Mounjaro for type 2 diabetes but exclude Zepbound for weight management, or require different prior authorization criteria for each.
Your medical record may read differently. A prescription written for diabetes care and a prescription written for obesity treatment can trigger different documentation, follow-up questions, and pharmacy workflows.
Your expectations may differ. Someone starting Mounjaro for A1C improvement may judge success differently than someone starting Zepbound for weight management. Both may see weight and metabolic effects, but the labeled indication frames the clinical conversation.
Can You Switch Between Mounjaro and Zepbound?
Sometimes, but it should be handled by your prescriber and pharmacy. Because the active ingredient is the same, a clinician may consider brand switching when coverage, supply, or indication changes. That does not mean you should treat the boxes as interchangeable on your own.
If you switch brands, confirm the exact dose, next injection date, and reason for the switch. The most important practical risk is accidentally duplicating doses or misunderstanding whether your schedule resets. Keep a written record of the last injection date, brand, dose, and injection site so the transition is clear.
If your switch is from semaglutide rather than between tirzepatide brands, read Switching From Ozempic to Mounjaro, because semaglutide and tirzepatide doses do not convert.
Tracking Mounjaro or Zepbound Without Mixing Up Your History
Tirzepatide schedules can involve several dated dose entries. The exact changes come from the prescriber and product label; a log simply preserves what was prescribed and administered.
A useful log should show:
- the exact medication name and dose,
- the injection date and site,
- any dose changes,
- weight or glucose trends you are following,
- side effects around step-up weeks.
OffGrid Dose is built for that kind of record. You can track the tirzepatide schedule, rotate injection sites, and keep a continuous timeline if your brand changes. The privacy-first GLP-1 tracker. OffGrid Dose does not receive health data or operate company cloud sync. Explore the features or start with the brand page that fits your prescription: Mounjaro tracker or Zepbound tracker.
Frequently Asked Questions
Are Mounjaro and Zepbound the same drug?
They contain the same active ingredient, tirzepatide. Their labels differ in indicated populations and product-specific instructions; consult the current labels linked above for the complete wording.
Is Zepbound stronger than Mounjaro?
They contain the same molecule and offer overlapping strengths. “Stronger” is not a label-defined comparison, and an individual's result cannot be predicted from a fixed checklist.
Do Mounjaro and Zepbound have the same side effects?
Their current labels list overlapping adverse reactions, including gastrointestinal reactions. Trial frequencies and personal risk should be interpreted from the exact product label and individual clinical context.
Can my pharmacy substitute one for the other?
Do not assume so. Even with the same active ingredient, substitutions depend on the prescription, state law, insurance rules, availability, and prescriber instructions. Ask your pharmacist and prescriber before changing brands.
Which tracker should I use if I switch brands?
Use a tracker that preserves the full tirzepatide timeline instead of forcing you to start over. OffGrid Dose supports tirzepatide tracking across brand-specific contexts, so your dose history remains understandable.
This article is for general educational purposes only and is not medical advice. Tirzepatide should be used only as prescribed, and decisions about brand, dose, indication, or switching should be made with your healthcare provider or pharmacist using the current FDA-approved label for your specific product.
Related Articles
Track this with OffGrid Dose
Log every dose, rotate injection sites, and watch your weight trend in a private local working log.
Mounjaro tracker →